FDA Clearance Tracker · P150027-S003
PD-L1 IHC 28-8 PHARMDX
Last checked: Nov 20, 2026Latest source record: Feb 24, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Feb 24, 2017
Approved
Time to decision
179 days
Received Aug 29, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P150027-S003
- Device name
- PD-L1 IHC 28-8 PHARMDX
- Applicant
- Dako North America, Inc.
- Applicant location
- Carpinteria, CA
- Received
- Aug 29, 2016
- Decided
- Feb 24, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P150027
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the updated product labeling and associated data.
Source documents
Other decisions for Dako North America, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K160922 · Decided May 3, 2016 · 29 days after receipt
Device type: Immunohistochemistry Assay, Antibody, Progesterone Receptor (MXZ) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.